ertugliflozin
Brand names: Steglatro
Steglatro is a drug that combines ertugliflozin and metformin. It helps lower blood sugar in adults with type 2 diabetes, along with diet and exercise.
Drug Pricing (NADAC)
Brand Price
$11.43/unit
Generic Available
No
MSD SUB MERCK
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Steglatro is used to help control blood sugar levels in adults with type 2 diabetes.
Common side effects
Diarrhea, Nausea, Vomiting
Key warnings
Steglatro contains metformin, which can cause a serious side effect called lactic acidosis.
How It Works
Steglatro contains two medicines. Ertugliflozin helps your kidneys remove sugar from your blood through urine. Metformin helps your body use insulin better and reduces sugar production in the liver.
How to Take It
Take Steglatro twice a day with meals. Your doctor will decide the right dose for you. They may increase your dose slowly to avoid stomach problems. Make sure to follow your doctor's instructions carefully.
Pregnancy & Breastfeeding
Steglatro may harm your unborn baby, especially during the second and third trimesters. Breastfeeding is not recommended while taking Steglatro. Talk to your doctor if you are pregnant or plan to become pregnant.
Missed Dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time.
Storage
Store Steglatro at room temperature (68°F-77°F) in a dry place, away from moisture.
Side Effects (from patient reports)
Based on 573 FDA adverse event reports.
FDA Adverse Event Report Analysis
Detailed analysis of 1,037 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
1,037
Death-Related Reports
12
Hospitalization Reports
290
Top Indication
Type 2 Diabetes Mellitus
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | NAUSEA | 86 |
| 2 | PRODUCT DOSE OMISSION ISSUE | 67 |
| 3 | URINARY TRACT INFECTION | 62 |
| 4 | VOMITING | 59 |
| 5 | FUNGAL INFECTION | 58 |
| 6 | NO ADVERSE EVENT | 55 |
| 7 | DIABETIC KETOACIDOSIS | 51 |
| 8 | BLOOD GLUCOSE INCREASED | 46 |
| 9 | DIZZINESS | 46 |
| 10 | DIARRHOEA | 43 |
| 11 | DRUG INEFFECTIVE | 41 |
| 12 | PRODUCT DOSE OMISSION | 29 |
| 13 | DECREASED APPETITE | 25 |
| 14 | DIABETES MELLITUS INADEQUATE CONTROL | 25 |
| 15 | RASH | 25 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Steglatro contains metformin, which can cause a serious side effect called lactic acidosis. This is a buildup of lactic acid in your blood. It can be life-threatening. Get medical help right away if you have symptoms like weakness, muscle pain, trouble breathing, stomach pain, or feel very sleepy.
Known Drug Interactions
7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2...
Mechanism: Taking these drugs together can increase the risk of a dangerous buildup of lactic acid in the blood, especially if the kidneys are not clearing the medicine properly.
What to do: Your doctor should monitor your kidney function and check for signs of acid buildup in your blood regularly.
7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin.
Mechanism: Topiramate affects how the body handles acid, which can increase the risk of a serious condition called lactic acidosis when combined with metformin.
What to do: Your doctor should monitor you closely for side effects and may need to adjust your medication.
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Mechanism: Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects.
What to do: Your doctor should carefully consider the risks and benefits of using these two medications at the same time.
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Mechanism: Ranolazine prevents the kidneys from properly filtering metformin out of the blood, which can lead to a higher amount of metformin in your system.
What to do: You and your doctor should discuss the risks of this combination and monitor for any signs of metformin toxicity.
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Mechanism: Cimetidine interferes with the body's ability to get rid of metformin through the kidneys, which can cause the drug to build up to unsafe levels.
What to do: Your healthcare provider should monitor you closely and decide if the benefits of taking both drugs are worth the risks.
Common Questions
What should I do if I feel sick to my stomach after taking Steglatro?
Can Steglatro be used for weight loss?
Will Steglatro cause me to have low blood sugar?
Can I drink alcohol while taking Steglatro?
What tests will my doctor do while I am taking Steglatro?
Can Steglatro cause urinary tract infections?
What if I need to have surgery or a procedure with contrast dye?
How long does it take for Steglatro to start working?
What are the symptoms of lactic acidosis?
Can Steglatro affect my bones?
What are the common side effects of ertugliflozin?
Does ertugliflozin interact with other medications?
What drug class is ertugliflozin?
Is ertugliflozin safe during pregnancy?
Related Medications in SGLT2 Inhibitor
Other drugs grouped near ertugliflozin — same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with ertugliflozin →
alogliptin
Nesina
Alogliptin and Metformin HCl is a drug that helps lower blood sugar in adults with type 2 diabetes.
Compare with ertugliflozin →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with ertugliflozin →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with ertugliflozin →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with ertugliflozin →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Related Health & Safety Data
🩺 Find a Doctor
Search prescribers for SGLT2 Inhibitor
🏨 Hospital Quality
CMS hospital ratings, safety scores & patient outcomes
💊 Supplement Data
NIH DSLD — check supplement ingredients & label claims
🍽️ Food Safety Alerts
FDA recalls, inspections & outbreak investigations
⚠️ Product Recalls
FDA, CPSC & NHTSA recall search
💉 Procedure Costs
Medicare procedure pricing for 9,297 procedures
Save on ertugliflozin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for ertugliflozin
The FDA label for ertugliflozin (sold under brand names such as Steglatro) classifies it as a prescription-only medication in the SGLT2 Inhibitor class. Steglatro is used to help control blood sugar levels in adults with type 2 diabetes. Official labeling lists 9 commonly reported side effects, including Diarrhea, Nausea, Vomiting.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 573 voluntary reports. The database also lists 8 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: December 20, 2024
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- FDA Orange Book — approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed — NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) — post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm — standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files — federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database — current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages